Consortium IO Logo

CONSORTIUM-IO (NCT04208958) is a first in-human Phase 1 study to evaluate safety, tolerability, PK/PD, and efficacy of VE800 in combination with Nivolumab in 111 adult subjects with certain types of cancer. The efficacy of this study will be measured by a total of overall response rate.

CONSORTIUM-IO is currently enrolling patients across the U.S. who have been diagnosed with melanoma, colorectal (CRC-MSS) cancer, and gastric/GEJ adenocarcinoma.  

For additional study information or to locate a study site near you, please visit  

If you have questions about the study or are interested in study participation, please email: